The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Gene Therapy For Parkinson’s Disease Market Be By 2030 Compared To Its 2026 Market Size?
The gene therapy for parkinson’s disease market size has seen rapid expansion over recent years. It is projected to grow from $0.64 billion in 2025 to $0.81 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.3%. This historical growth can be attributed to advancements in viral vector engineering, a deeper understanding of parkinson’s disease pathology, increased neuroscience research funding, the availability of improved delivery technologies, and successful early clinical trials.
The market size for gene therapy designed to treat Parkinson’s disease is anticipated to experience substantial expansion in the coming years. It is projected to achieve a value of $2.05 billion by 2030, progressing at a compound annual growth rate (CAGR) of 26.0%. This growth during the forecast period can be attributed to factors such as increasing investments in therapies for neurodegenerative diseases, a growing adoption of personalized gene therapy techniques, the broadening of late-stage clinical pipelines, a rising demand for treatments that modify disease progression, and advancements in minimally invasive delivery methods. Key trends during this period are expected to include the increasing development of viral vector-based therapies, a heightened focus on approaches for dopamine restoration, expanded utilization of neurotrophic factor gene delivery, the proliferation of precision intracerebral delivery techniques, and an enhanced emphasis on achieving long-term therapeutic efficacy.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28231&type=smp
What Primary Drivers Are Shaping The Gene Therapy For Parkinson’s Disease Market?
The expanding enthusiasm for personalized medicine is projected to stimulate the expansion of the gene therapy for Parkinson’s disease market in the future. Personalized medicine is defined as a medical methodology that customizes treatment and prevention plans based on an individual’s genetic makeup, lifestyle, and environmental factors. The appeal of personalized medicine is increasing, driven by a rising need for targeted treatments that enhance therapeutic efficacy while reducing negative side effects. Within personalized medicine, gene therapy for Parkinson’s disease utilizes the delivery of customized genetic alterations to reinstate dopamine function and target disease mechanisms specific to individual patients. For example, in February 2024, the US-based non-profit organization, the Personalized Medicine Coalition, indicated that in 2023, the US Food and Drug Administration (FDA) approved 16 new personalized treatments for patients with rare diseases, a significant leap from the 6 approvals observed in 2022. Consequently, the rising focus on personalized medicine is propelling the development of the gene therapy for Parkinson’s disease market.
How Is The Gene Therapy For Parkinson’s Disease Market Organized By Segment Classification?
The gene therapy for parkinson’s disease market covered in this report is segmented –
1) By Therapy Type: In Vivo Gene Therapy, Ex Vivo Gene Therapy
2) By Vector Type: Viral Vectors, Non-Viral Vectors
3) By Target Gene: Aromatic L-Amino Acid Decarboxylase (AADC), Glial Cell Line-Derived Neurotrophic Factor (GDNF), Neurturin, Other Target Genes
4) By Delivery Method: Intracerebral, Intravenous, Other Delivery Methods
5) By End-User: Hospitals, Specialty Clinics, Research Institutes, Other End-Users
Subsegments:
1) By In Vivo Gene Therapy: Viral Vectors, Non-Viral Vectors
2) By Ex Vivo Gene Therapy: Autologous Cell-Based Gene Therapy, Allogeneic Cell-Based Gene Therapy
What Trends Are Shaping The Future Of The Gene Therapy For Parkinson’s Disease Market?
Leading companies are actively involved in the gene therapy for Parkinson’s disease market, with efforts concentrated on developing more precise treatments, such as regenerative medicine advanced therapy, to improve neuronal survival, restore dopamine function, and offer long-lasting disease-modifying benefits for patients afflicted with Parkinson’s disease. Regenerative medicine advanced therapy (RMAT) refers to a specific United States Food and Drug Administration (FDA) designation granted to various regenerative medicine products, including cell therapies, gene therapies, and tissue-engineered products, which are designed to treat, modify, reverse, or cure serious or life-threatening ailments. For instance, in February 2025, Asklepios BioPharmaceutical, Inc. (AskBio), a US-based gene therapy company, introduced AB-1005, an investigational AAV2-GDNF gene therapy that was awarded FDA regenerative medicine advanced therapy (RMAT) designation. This designation, intended to accelerate the development and review of promising therapies, was given based on data provided by AskBio, which included clinical evidence from its Phase Ib open-label, uncontrolled trial, demonstrating AB-1005’s capacity to slow the progression of the disease and enhance motor function in Parkinson’s patients.
Who Are The Industry Participants Involved In The Gene Therapy For Parkinson’s Disease Market?
Major companies operating in the gene therapy for parkinson’s disease market are Merck & Co. Inc., Bayer AG, Sanofi S.A., Eli Lilly and Company, Biogen Inc., PTC Therapeutics Inc., Zambon S.p.A., Oxford BioMedica plc, Voyager Therapeutics Inc., Insilico Medicine Inc., Spur Therapeutics Inc., Cerevance Inc., MeiraGTx Holdings plc, BlackfinBio Inc., Partner Therapeutics Inc., Kenai Therapeutics Inc., CureSen Therapeutics Inc., BioVie Inc., Clexio Biosciences Ltd., Tetraneuron S.L.
Get The Full Gene Therapy For Parkinson’s Disease Market Report:
Which Region Holds The Highest Market Share In The Gene Therapy For Parkinson’s Disease Market?
North America was the largest region in the gene therapy for parkinson’s disease market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gene therapy for parkinson’s disease market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Gene Therapy For Parkinson’s Disease Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Gene Therapy For Parkinson’s Disease Market 2026, By The Business Research Company
Genes Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/genes-therapy-global-market-report
Anti Parkinson Drugs Market Report 2026
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report
Nucleic Acid Based Gene Therapy Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model